Previous studies have shown that ADAM17 is upregulated in most tumor cells.57 Activated ADAM17 markedly reduced the impact of chemotherapy on tumor growth and cell apoptosis, thereby mediating chemotherapy resistance.58 Therefore, it is necessary to determine whether ADAM17 as a cardioprotective target interferes with the anti-tumor effects of doxorubicin. This evidence concerns the gene ADAM17 and neoplasm.